



where  $n$  is the number of compartments,  $\lambda_i$  the exponential parameter, and  $A$  the coefficient matrix.

It should be noted that in Eq.(3) from the second formula to the  $n$ -th have similar form, so their roots must be the same. Therefore, if

one equation of them is solved, all of  $n-1$  roots can be obtained at the same time, which are  $k_{21}, k_{31}, \dots, k_{n1}$ .

In addition, elements  $a_{ij}$  of matrix  $A$  suit for the following formula<sup>[2]</sup>

$$\frac{k_{ji}}{k_{ij} - \lambda_j} a_{1j} = a_{ij} \quad (i = 2, 3, \dots, n; \quad j = 2, 3, \dots, n) \quad (4)$$

According to formula (4),  $k_{12}, k_{13}, \dots, k_{1n}$  can be easily calculated after  $k_{21}, k_{31}, \dots, k_{n1}$  are obtained.

Now we select the second formula in Eq.(3) as an example for evaluation of the equations.

$$\frac{a_{11}}{k_{21} - \lambda_1} + \frac{a_{12}}{k_{21} - \lambda_2} + \dots + \frac{a_{1n}}{k_{21} - \lambda_n} = 0$$

The equation has several singular points which will result in divergence during solving process. It can be changed into

$$a_{11}(k_{21} - \lambda_2)(k_{21} - \lambda_3) \dots (k_{21} - \lambda_n) + a_{12}(k_{21} - \lambda_1)(k_{21} - \lambda_3) \dots (k_{21} - \lambda_n) \\ + \dots + a_{1n}(k_{21} - \lambda_1)(k_{21} - \lambda_2) \dots (k_{21} - \lambda_{n-1}) = 0 \quad (5)$$

These terms in Eq.(5) can be expanded as

$$a_{11}(k_{21} - \lambda_2)(k_{21} - \lambda_3) \dots (k_{21} - \lambda_n) \\ = a_{11}[k_{21}^{n-1} - \sum_{\substack{i=2 \\ i \neq 1}}^n \lambda_i k_{21}^{n-2} + \sum_{\substack{i=2 \\ i \neq 1 \\ j \neq i}}^n \lambda_i \lambda_j k_{21}^{n-3} - \dots + (-1)^{n-1} \prod_{\substack{i=2 \\ i \neq 1}}^n \lambda_i] \\ a_{12}(k_{21} - \lambda_1)(k_{21} - \lambda_3) \dots (k_{21} - \lambda_n) \\ = a_{12}[k_{21}^{n-1} - \sum_{\substack{i=1 \\ i \neq 2}}^n \lambda_i k_{21}^{n-2} + \sum_{\substack{i=1 \\ i \neq 2 \\ j \neq i}}^n \lambda_i \lambda_j k_{21}^{n-3} - \dots + (-1)^{n-1} \prod_{\substack{i=1 \\ i \neq 2}}^n \lambda_i] \\ \dots \dots \dots a_{1n}(k_{21} - \lambda_1)(k_{21} - \lambda_2) \dots (k_{21} - \lambda_{n-1}) \\ = a_{1n}[k_{21}^{n-1} - \sum_{\substack{i=1 \\ i \neq n}}^n \lambda_i k_{21}^{n-2} + \sum_{\substack{i=1 \\ i \neq n \\ j \neq i}}^n \lambda_i \lambda_j k_{21}^{n-3} - \dots + (-1)^{n-1} \prod_{\substack{i=1 \\ i \neq n}}^{n-1} \lambda_i]$$

The  $n-1$  order higher degree equation about  $k_{21}$  can be obtained by summing these coefficients corresponding to each  $k_{21}^i (i=0, 1, 2, \dots, n-1)$ .

We select the third term of the first equation  $\sum_{i=2}^n \lambda_i \lambda_j k_{21}^{n-3} (i \neq 1, j \neq i)$  as an example to analyse these coefficients of  $k_{21}^i$ . In fact,

the coefficient is the sum of some combinations of  $\lambda_i$  and  $\lambda_j$  with  $i \neq 1$  and  $j \neq i$ . It means that two elements are taken from  $n$  elements to combine and several combinations are rejected, which are not suitable to the condition, and the other combinations then are summed. Such a combination can be called as conditional combi-

nation. According to this method, we compiled the conditional combination software to calculate coefficients. The other coefficients of  $k_{21}^i$  are all conditional combinations, and their calculations are similar to the above one.

$k_{21}, k_{31}, \dots, k_{n1}$  can be calculated by terms of Eq.(5) replaced with their expanded forms. Using Eq.(4),  $k_{12}, k_{13}, \dots, k_{1n}$  are also obtained.

According to above formulae, we have compiled the computer program named "Rate" with the C language for calculation.

### 3 Computer program

The computer program "Rate" consists of three parts: PLM<sup>[3]</sup>, COM (combination) and HDE (high degree equation). PLM is used to calculate pharmacokinetic equation, matrix  $A$ ,

$\lambda_i$  and other data. COM is used to obtain a varied combinations of  $\lambda_1, \lambda_2, \dots, \lambda_n$ . HDE is used to calculate rate constants. The process of calculation is: inputting experimental data  $\rightarrow$  PLM  $\rightarrow$  COM  $\rightarrow$  HDE  $\rightarrow$  outputting results.

### 4 Calculation

We used the method to deal with animal (rats) experimental data of  $^{125}\text{I}$ -bivalent ligand of practolol ( $^{125}\text{I}$ -BAP), a myocardial receptor imaging agent, and to calculate the rate constants of the animal experiment. We select a slightly higher compartment number  $n=4$ . First, we calculated matrix  $A$  and exponential parameters  $\lambda_i$  ( $i=1\sim 4$ ) by pharmacokinetics local model.<sup>[3]</sup> Then, using the program, we obtained rate constants  $k_{i1}$  and  $k_{1i}$ . The results are listed in Table 1.

Table 1 The calculated results of rate constants for  $^{125}\text{I}$ -BAP

Time/min	3	5	15	30	60	120	240	480	720
Experimental data*	1.12	0.92	0.53	0.27	0.17	0.13	0.08	0.04	0.02
Calculated data*	1.12	0.92	0.41	0.20	0.13	0.09	0.06	0.02	0.01
Equation	$C=1.0005\exp(-0.1376t)+0.3692\exp(-0.0676t)+0.1178\exp(-0.0049t)+0.0400\exp(-0.0029t)$								
Matrix $A$	$\begin{pmatrix} 1.0005 & 0.3692 & 0.1178 & 0.0400 \\ -0.2231 & 0.2022 & 0.0158 & 0.0052 \\ -0.5956 & -0.5115 & 0.8629 & 0.2442 \\ -0.0549 & -0.0424 & -0.5606 & 0.6574 \end{pmatrix}$								
$\lambda_i$	$\lambda_1 = 0.1376 \quad \lambda_2 = 0.0676 \quad \lambda_3 = 0.0049 \quad \lambda_4 = 0.0029$								
Rate constant	$k_{12}=0.0111 \quad k_{13}=0.0731 \quad k_{14}=0.0074$ $k_{21}=0.0879 \quad k_{31}=0.0149 \quad k_{41}=0.0033$								

\*Unit is (MBq/g specimens found)/(MBq administered body weight)

### 5 Summary

The calculation of rate constant in situation of small number of compartments can be done according to some formulae.<sup>[1,2]</sup> But with increasing compartment number, the calculation is tending to more and more complex, which makes solving rate constants very difficult. Our method based on a general principle simplifies the process of solving rate constants.

Rate constants are very useful in nuclear medicine, such as in study of radiopharmaceuticals, especially imaging agent, in nuclide therapy and in internal radiation. In combination

with the local model, they can describe pharmacokinetics action of radiopharmaceutical in blood and in any organ, and provide a lot of useful information to direct our work.

### References

- 1 Gibaldi M, Perrier D. Pharmacokinetics. Second Edition, Revised and Expanded. New York: Marcel Dekker, 1982
- 2 Liu Chang-Xiao, Liu Ding-Yuan. Introduction of pharmacokinetics (in Chinese). Beijing: China Academic Publishing House, 1984
- 3 Cao Guo-Xian, Li Wei-Yi, Yu Hui-Xin. Nucl Sci Tech, 1996; 7:170